Daniel Vitt, Immunic Therapeutics CEO
Immunic reports another trial flop, and execs blame 'confounded' placebo response as shares sink
Four months after taking an axe to the pipeline resulting from a Phase II miss, Immunic is back with another miss.
On Thursday afternoon, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
